演題詳細

一般口演 / Oral Session

一般口演 2 (Oral Session 2) :鉄キレート療法

print

日程
2013年10月11日(金)
時間
10:30 - 11:30
会場
第3会場 / Room No.3 (さっぽろ芸文館 3F 蓬莱)
座長・司会
金森 平和 (Heiwa Kanamori):1
1:神奈川県立がんセンター 血液内科
 
前へ戻る

Deferasirox in iron-overloaded patients with hematologic diseases at Saga University Hospital

演題番号 : OS-1-10

安部 乙峰 (Otone Abe):1、吉原 麻里 (Mari Yoshihara):2、久保田 寧 (Yasushi Kubota):2,3、末岡 榮三朗 (Eisaburo Sueoka):3、蒲池 和晴 (Kazuharu Kamachi):2、北村 浩晃 (Hiroaki Kitamura):2、板村 英和 (Hidekazu Itamura):2、西 眞範 (Masanori Nishi):4、進藤 岳郎 (Takero Shindo):2、福島 伯泰 (Noriyasu Fukushima):2、濱崎 雄平 (Yuhei Hamasaki):4、木村 晋也 (Shinya Kimura):2

1:Center for Graduate Medical Education Development and Research, Saga University、2:Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University、3:Department of Transfusion Medicine, Saga University Hospital、4:Department of Pediatrics, Faculty of Medicine, Saga University

 

Regular transfusion lead to the occurrence of iron overload (IO), which can cause severe damage to the heart, liver, and endocrine glands. Deferasirox (DFX) is a once-daily, and oral iron chelator approved for the treatment of chronic IO due to frequent blood transfusions. Recently, hematological improvements in myelodysfunction transfusion-dependent patients with during iron-chelation therapy have been reported. We conducted a retrospective survey to clarify the efficacy and safety of DFX in our hospital from January 2007 to February 2013. A total of 19 persons had received iron chelation therapy using DFX; 6 aplastic anemia, 4 pure red cell aplasia and 2 MDS. The average age was 59 years old (3-86). The average of the total amounts of transfusion before and after administration of DFX medication were 60 units, and after 26 units of red cell concentrate, respectively. The duration of administration was various from several to 40 months, and dose reduction of DFX was required in several cases because of the renal damage. The serum ferritin concentration decreased clearly in 3/19 patients, but increased in several cases. During DFX treatment, erythroid responses were observed in 15.7% (3/19) of patients and the transfusion interval extended. In particular two of these 3 cases needed no more transfusions. On the other hand, four patients (21%) discontinued because of an the occurrence of adverse events. Our cases suggest that adequate iron chelation may lead hematopoietic recovery in some IO patients although careful management of adverse events by DFX is needed.

前へ戻る